Works by Taniguchi, Yoshihiko


Results: 41
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).

    Published in:
    Clinical Lung Cancer, 2024, v. 25, n. 7, p. 643, doi. 10.1016/j.cllc.2024.07.014
    By:
    • Hayato Kawachi;
    • Motohiro Tamiya;
    • Yuko Oya;
    • Go Saito;
    • Yoshihiko Taniguchi;
    • Hirotaka Matsumoto;
    • Yuki Sato;
    • Taiichiro Otsuki;
    • Hidekazu Suzuki;
    • Yasushi Fukuda;
    • Satoshi Tanaka;
    • Yoko Tsukita;
    • Junji Uchida;
    • Yoshihiko Sakata;
    • Yuki Nakatani;
    • Ryota Shibaki;
    • Daisuke Arai;
    • Asuka Okada;
    • Satoshi Hara;
    • Koichi Takayama
    Publication type:
    Article
    10
    11

    Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

    Published in:
    2020
    By:
    • Hosoya, Kazutaka;
    • Fujimoto, Daichi;
    • Morimoto, Takeshi;
    • Kumagai, Toru;
    • Tamiya, Akihiro;
    • Taniguchi, Yoshihiko;
    • Yokoyama, Toshihide;
    • Ishida, Tadashi;
    • Hirano, Katsuya;
    • Matsumoto, Hirotaka;
    • Kominami, Ryota;
    • Tomii, Keisuke;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Kanazu, Masaki;
    • Sawa, Nobuhiko;
    • Makio, Takeshi;
    • Hara, Satoshi
    Publication type:
    journal article
    12
    13

    Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.

    Published in:
    PLoS ONE, 2019, v. 14, n. 7, p. 1, doi. 10.1371/journal.pone.0220570
    By:
    • Ryuya Edahiro;
    • Masaki Kanazu;
    • Hiroyuki Kurebe;
    • Masahide Mori;
    • Daichi Fujimoto;
    • Yoshihiko Taniguchi;
    • Hidekazu Suzuki;
    • Katsuya Hirano;
    • Toshihide Yokoyama;
    • Mitsunori Morita;
    • Yasushi Fukuda;
    • Junji Uchida;
    • Takeshi Makio;
    • Motohiro Tamiya
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20
    21

    Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.

    Published in:
    JAMA Network Open, 2023, v. 6, n. 2, p. e230698, doi. 10.1001/jamanetworkopen.2023.0698
    By:
    • Fujimoto, Daichi;
    • Morimoto, Takeshi;
    • Tamiya, Motohiro;
    • Hata, Akito;
    • Matsumoto, Hirotaka;
    • Nakamura, Atsushi;
    • Yokoyama, Toshihide;
    • Taniguchi, Yoshihiko;
    • Uchida, Junji;
    • Sato, Yuki;
    • Yokoi, Takashi;
    • Tanaka, Hisashi;
    • Furuya, Naoki;
    • Masuda, Takeshi;
    • Sakata, Yoshihiko;
    • Miyauchi, Eisaku;
    • Hara, Satoshi;
    • Saito, Go;
    • Miura, Satoru;
    • Kanazu, Masaki
    Publication type:
    Article
    22
    23

    Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience.

    Published in:
    Clinical Medicine Insights: Oncology, 2019, v. 13, p. N.PAG, doi. 10.1177/1179554918821314
    By:
    • Takeda, Maiko;
    • Kasai, Takahiko;
    • Naito, Maiko;
    • Tamiya, Akihiro;
    • Taniguchi, Yoshihiko;
    • Saijo, Nobuhiko;
    • Naoki, Yoko;
    • Okishio, Kyoichi;
    • Shimizu, Shigeki;
    • Kojima, Kensuke;
    • Nagoya, Akihiro;
    • Sakamoto, Tetsuki;
    • Utsumi, Tomoki;
    • Yoon, Hyung-Eun;
    • Matsumura, Akihide;
    • Atagi, Shinji
    Publication type:
    Article
    24

    Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience.

    Published in:
    Clinical Medicine Insights: Oncology, 2019, v. 13, p. N.PAG, doi. 10.1177/1179554918821314
    By:
    • Takeda, Maiko;
    • Kasai, Takahiko;
    • Naito, Maiko;
    • Tamiya, Akihiro;
    • Taniguchi, Yoshihiko;
    • Saijo, Nobuhiko;
    • Naoki, Yoko;
    • Okishio, Kyoichi;
    • Shimizu, Shigeki;
    • Kojima, Kensuke;
    • Nagoya, Akihiro;
    • Sakamoto, Tetsuki;
    • Utsumi, Tomoki;
    • Yoon, Hyung-Eun;
    • Matsumura, Akihide;
    • Atagi, Shinji
    Publication type:
    Article
    25

    Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status.

    Published in:
    BMC Pulmonary Medicine, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12890-024-03212-5
    By:
    • Taniguchi, Yoshihiko;
    • Tamiya, Akihiro;
    • Osuga, Mitsuo;
    • Harada, Daijiro;
    • Isa, Shun-ichi;
    • Nakamura, Keiichi;
    • Mizumori, Yasuyuki;
    • Shinohara, Tsutomu;
    • Yanai, Hidetoshi;
    • Nakatomi, Katsumi;
    • Oki, Masahide;
    • Mori, Masahide;
    • Kuwako, Tomohito;
    • Yamazaki, Koji;
    • Tamura, Atsuhisa;
    • Ando, Masahiko;
    • Koh, Yasuhiro
    Publication type:
    Article
    26

    Circulating Tumour DNA in Patients With EGFR‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study.

    Published in:
    Cancer Medicine, 2025, v. 14, n. 7, p. 1, doi. 10.1002/cam4.70861
    By:
    • Tamiya, Akihiro;
    • Mizumori, Yasuyuki;
    • Osuga, Mitsuo;
    • Isa, Shun‐ichi;
    • Taniguchi, Yoshihiko;
    • Nakamura, Keiichi;
    • Harada, Daijiro;
    • Shinohara, Tsutomu;
    • Yanai, Hidetoshi;
    • Nakatomi, Katsumi;
    • Oki, Masahide;
    • Mori, Masahide;
    • Kuwako, Tomohito;
    • Yamazaki, Koji;
    • Tamura, Atsuhisa;
    • Ando, Masahiko;
    • Koh, Yasuhiro
    Publication type:
    Article
    27

    Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.

    Published in:
    Nature Communications, 2020, v. 11, n. 1, p. N.PAG, doi. 10.1038/s41467-020-18442-4
    By:
    • Wang, Rong;
    • Yamada, Tadaaki;
    • Kita, Kenji;
    • Taniguchi, Hirokazu;
    • Arai, Sachiko;
    • Fukuda, Koji;
    • Terashima, Minoru;
    • Ishimura, Akihiko;
    • Nishiyama, Akihiro;
    • Tanimoto, Azusa;
    • Takeuchi, Shinji;
    • Ohtsubo, Koshiro;
    • Yamashita, Kaname;
    • Yamano, Tomoyoshi;
    • Yoshimura, Akihiro;
    • Takayama, Koichi;
    • Kaira, Kyoichi;
    • Taniguchi, Yoshihiko;
    • Atagi, Shinji;
    • Uehara, Hisanori
    Publication type:
    Article
    28

    LETTERS TO THE EDITOR.

    Published in:
    Kidney International, 1998, v. 54, n. 6, p. 2245
    By:
    • Taniguchi, Yoshihiko;
    • Yorioka, Noriaki;
    • Yamashita, Kazuomi;
    • Masaki, Takao;
    • Yamakido, Michio
    Publication type:
    Article
    29

    Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.

    Published in:
    Oncologist, 2024, v. 29, n. 2, p. e282, doi. 10.1093/oncolo/oyad245
    By:
    • Hasegawa, Takaaki;
    • Okuyama, Toru;
    • Uemura, Takehiro;
    • Matsuda, Yoshinobu;
    • Otani, Hiroyuki;
    • Shimizu, Junichi;
    • Horio, Yoshitsugu;
    • Watanabe, Naohiro;
    • Yamaguchi, Teppei;
    • Fukuda, Satoshi;
    • Oguri, Tetsuya;
    • Maeno, Ken;
    • Taniguchi, Yoshihiko;
    • Nosaki, Kaname;
    • Fukumitsu, Kensuke;
    • Akechi, Tatsuo
    Publication type:
    Article
    30
    31
    32
    33
    34
    35

    Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.

    Published in:
    Investigational New Drugs, 2025, v. 43, n. 1, p. 101, doi. 10.1007/s10637-024-01500-9
    By:
    • Taniguchi, Yoshihiko;
    • Tamiya, Akihiro;
    • Osuga, Mitsuo;
    • Isa, Shun-ichi;
    • Nakamura, Keiichi;
    • Mizumori, Yasuyuki;
    • Shinohara, Tsutomu;
    • Yanai, Hidetoshi;
    • Nakatomi, Katsumi;
    • Oki, Masahide;
    • Mori, Masahide;
    • Kuwako, Tomohito;
    • Yamazaki, Koji;
    • Shimada, Masahiro;
    • Ando, Masahiko;
    • Koh, Yasuhiro
    Publication type:
    Article
    36

    Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 4, p. 1106, doi. 10.1007/s10637-021-01076-8
    By:
    • Tamiya, Motohiro;
    • Tamiya, Akihiro;
    • Suzuki, Hidekazu;
    • Taniguchi, Yoshihiko;
    • Katayama, Kanako;
    • Minomo, Shojiro;
    • Nakao, Keiko;
    • Takeuchi, Naoko;
    • Matsuda, Yoshinobu;
    • Naito, Yujiro;
    • Shiroyama, Takayuki;
    • Okamoto, Norio;
    • Okishio, Kyoichi;
    • Kumagai, Toru;
    • Atagi, Shinji;
    • Imamura, Fumio;
    • Hirashima, Tomonori
    Publication type:
    Article
    37

    Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).

    Published in:
    Investigational New Drugs, 2019, v. 37, n. 6, p. 1266, doi. 10.1007/s10637-019-00843-y
    By:
    • Tamiya, Motohiro;
    • Tamiya, Akihiro;
    • Hosoya, Kazutaka;
    • Taniguchi, Yoshihiko;
    • Yokoyama, Toshihide;
    • Fukuda, Yasushi;
    • Hirano, Katsuya;
    • Matsumoto, Hirotaka;
    • Kominami, Ryota;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Kanazu, Masaki;
    • Sawa, Nobuhiko;
    • Kinoshita, Yoshinori;
    • Hara, Satoshi;
    • Kumagai, Toru;
    • Fujimoto, Daichi
    Publication type:
    Article
    38

    Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study.

    Published in:
    European Journal of Clinical Pharmacology, 2023, v. 79, n. 4, p. 503, doi. 10.1007/s00228-023-03452-0
    By:
    • Tanizaki, Satoshi;
    • Matsumoto, Kinnosuke;
    • Tamiya, Akihiro;
    • Taniguchi, Yoshihiko;
    • Matsuda, Yoshinobu;
    • Uchida, Junji;
    • Ueno, Kiyonobu;
    • Kawachi, Hayato;
    • Tamiya, Motohiro;
    • Yanase, Takafumi;
    • Suzuki, Hidekazu;
    • Okishio, Kyoichi
    Publication type:
    Article
    39

    Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias.

    Published in:
    Respirology, 2019, v. 24, n. 7, p. 658, doi. 10.1111/resp.13514
    By:
    • Arai, Toru;
    • Kida, Hiroshi;
    • Ogata, Yoshitaka;
    • Marumo, Satoshi;
    • Matsuoka, Hiroto;
    • Gohma, Iwao;
    • Yamamoto, Suguru;
    • Mori, Masahide;
    • Sugimoto, Chikatoshi;
    • Tachibana, Kazunobu;
    • Akira, Masanori;
    • Edahiro, Ryuya;
    • Hamasaki, Toshimitsu;
    • Inoue, Yoshikazu;
    • Taniguchi, Yoshihiko;
    • Minomo, Shojiro;
    • Tsuji, Taisuke;
    • Kimura, Yohei;
    • Saijo, Nobuhiko;
    • Sasaki, Yumiko
    Publication type:
    Article
    40
    41

    Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.

    Published in:
    2021
    By:
    • Hosoya, Kazutaka;
    • Fujimoto, Daichi;
    • Morimoto, Takeshi;
    • Kumagai, Toru;
    • Tamiya, Akihiro;
    • Taniguchi, Yoshihiko;
    • Yokoyama, Toshihide;
    • Ishida, Tadashi;
    • Matsumoto, Hirotaka;
    • Hirano, Katsuya;
    • Kominami, Ryota;
    • Tomii, Keisuke;
    • Suzuki, Hidekazu;
    • Hirashima, Tomonori;
    • Tanaka, Satoshi;
    • Uchida, Junji;
    • Morita, Mitsunori;
    • Kanazu, Masaki;
    • Mori, Masahide;
    • Nagata, Kenji
    Publication type:
    journal article